Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma

Next Previous
X
Search
Trial Profile

A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemcentinib (Primary) ; Dabrafenib; Pembrolizumab; Trametinib
  • Indications Malignant melanoma; Skin cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 18 Jun 2024 Status changed from active, no longer recruiting to completed.
    • 24 Oct 2023 Interim Results ( database lock on August 21 2023) assessing safety and efficacy of bemcentinib in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma presented at the 48th European Society for Medical Oncology Congress
    • 23 Oct 2023 According to a BerGenBio media release, results from this study were presented during the European Society of Clinical Oncologists (ESMO) Annual Meeting 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top